Market/Novel Tech

Pixium SA has announced the completion of implantations of the “PRIMAvera” trial with the implantation of a bionic artificial retina.

A French bioelectronics company “Pixium Vision SA” (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), based in Paris, has announced the completion of implantations of an… Read More »Pixium SA has announced the completion of implantations of the “PRIMAvera” trial with the implantation of a bionic artificial retina.

Nanoscope Therapeutics Inc., have announced the completion of enrolment for Phase 2 Stargardt disease study with optogenetic gene therapy 

Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported the completion of enrollment for a Phase 2 study for Stargardt disease.  The study… Read More »Nanoscope Therapeutics Inc., have announced the completion of enrolment for Phase 2 Stargardt disease study with optogenetic gene therapy 

Opus Genetics (Raleigh, North Carolina) has announced new preclinical data from studies evaluating gene therapies for OPGx-001 and OPGx-002.

Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced new preclinical data from studies evaluating gene therapies, termed… Read More »Opus Genetics (Raleigh, North Carolina) has announced new preclinical data from studies evaluating gene therapies for OPGx-001 and OPGx-002.

Regenxbio Inc.’s gene therapy treatment (RGX-314) for diabetic retinopathy (DR) reports positive interim data from Phase II.

REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company, based in Rockville, Maryland, has reported positive interim data from an ongoing Phase II “ALTITUDE” trial of… Read More »Regenxbio Inc.’s gene therapy treatment (RGX-314) for diabetic retinopathy (DR) reports positive interim data from Phase II.